EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term outcomes of blue light laser therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia within a multimodal treatment concept

Christina Heiß, Christopher Bohr, Thomas S Kühnel, Karolina Müller, Florian Zeman, Kornelia E C Andorfer

European Archives of Oto-Rhino-Laryngology · 2026

DOI: 10.1007/s00405-025-09919-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2026. Verfasst von Christina Heiß und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. Christina.Heiss@extern.un…. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Epistaxis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Regensburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hereditary hemorrhagic telangiectasia (HHT) is a genetically inherited vascular disorder transmitted in an autosomal dominant manner. It is defined by the presence of arteriovenous malformations in the nasal mucosa, resulting in severe recurrent epistaxis. This study investigates the long-term efficacy and safety of blue light laser therapy for managing epistaxis in patients with HHT.

Methods

A retrospective analysis was conducted on 71 patients treated between 09/2017 and 02/2023 at the Department of Otorhinolaryngology, University Hospital Regensburg. All patients underwent endonasal treatment using a pulsed diode laser at 445 nm as part of a structured stepwise protocol including nasal care. Of the 86 patients initially treated, 17.4% were excluded due to uncontrollable epistaxis requiring surgery under general anesthesia or concomitant medication.

Results

A total of 351 laser treatments were administered, with no reported occurrences of nasal septal perforation. A modified Epistaxis Severity Score (ESS, range 0–10) decreased by an estimated mean difference of –0.66 (95% CI = –1.05, –0.27). Subgroup analyses revealed that patients with moderate to severe baseline ESS experienced a significant reduction of –1.53 (95% CI = –2.11, –0.95), achieving the minimal important difference (MID) of 0.71. Patients’ satisfaction with their nasal bleeding, measured by the Numeric Rating Scale (0–10), improved significantly from 5.08 to 6.67 ( p < 0.001).

Conclusions

Our study indicates that blue light laser therapy plus mucosal care is associated with reduced nosebleed severity, improved patient satisfaction and a favorable safety profile, supporting its use as a long-term treatment option for managing HHT in patients with mild to moderate epistaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Telangiectasia, Hereditary HemorrhagicEpistaxisHumansFemaleMaleRetrospective StudiesBlue LightTreatment OutcomeMiddle AgedAdultAgedCombined Modality TherapyAdolescent

Stichwörter der Autor:innen

Blue light laserEpistaxisEpistaxis Severity ScoreHHTHereditary hemorrhagic telangiectasiaLaser

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. Christina.Heiss@extern.uni-regensburg.de.
  • Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
  • Center for Clinical Studies, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.

Förderung

  • Universitätsklinikum Regensburg

Zitieren

APA

Heiß, C., Bohr, C., Kühnel, T. S., Müller, K., Zeman, F., & Andorfer, K. E. C. (2026). Long-term outcomes of blue light laser therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia within a multimodal treatment concept. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-025-09919-3

Vancouver

Heiß C, Bohr C, Kühnel TS, Müller K, Zeman F, Andorfer KEC. Long-term outcomes of blue light laser therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia within a multimodal treatment concept. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-025-09919-3

BibTeX
@article{Hei2026,
  author = {Heiß, Christina and Bohr, Christopher and Kühnel, Thomas S and Müller, Karolina and Zeman, Florian and Andorfer, Kornelia E C},
  title = {Long-term outcomes of blue light laser therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia within a multimodal treatment concept},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  doi = {10.1007/s00405-025-09919-3}
}
Kostenlos starten →